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Abstract: Evidence-based medicine has become associated with a preference for  random-
ized trials. Randomization is a powerful tool against both known and unknown confounding. 
However, due to cost-induced constraints in size,  randomized trials are seldom able to provide 
the subgroup analyses needed to gain much insight into effect modification. To apply results 
to an individual patient, effect modification needs to be considered. Results from  randomized 
trials are therefore often difficult to apply in daily clinical practice. Confounding by indica-
tion, which randomization aims to prevent, is caused by more severely ill patients being less 
or more likely to be treated. Therefore, the prognostic indicators that physicians use to make 
treatment decisions become confounders. However, these same prognostic indicators are also 
effect modifiers. This is in fact exactly why they are relevant to decision-making. We use simple, 
fictive numerical examples to illustrate these concepts. Then we argue that if we would record 
all relevant variables, it would simultaneously solve the problem of confounding by indication 
and allow quantification of effect modification. It has previously been argued that it is practi-
cally more feasible to “simply”  randomize treatment allocation, than to adequately correct for 
confounding by indication. We will argue that, in the current age of evidence-based medicine 
and highly regulated  randomized trials, this balance has shifted. We therefore call for better 
observational clinical research. However, careless acceptance of results from poorly performed 
observational research can lead clinicians seriously astray. Therefore, a more interactive approach 
toward the medical literature might be needed, where more room is made for scientific discus-
sion and interpretation of results, instead of one-way reporting.
Keywords: treatment, personalized, effectiveness, effect modification, risk factors, confound-
ing by indication
Introduction
Randomized trials are considered the gold standard for establishing effectiveness of 
treatments.1 Therefore it is tempting to consider all other types of clinical research as 
“what you’re stuck with if a randomized trial is impossible.” To determine whether 
this, somewhat derogative, attitude toward observational research is justified, we should 
first consider why a randomized trial provides such highly reliable evidence. Proper 
consideration of the strengths of randomized trials will provide clear guidance on 
when a randomized trial is absolutely indicated. Conversely, it will also hint at when 
a randomized trial could be either unnecessary or even contraindicated.
It has previously been reasoned that confounding by indication, which random-
ized trials aim to prevent, could also be corrected for in data analyses if treatment 
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allocation decisions could be adequately modeled.2,3 This 
was, however, considered very difficult. Therefore it was 
considered more practically feasible to avoid confounding 
by indication all together, by performing a randomized 
trial. Furthermore, it was proposed that allocation of treat-
ment is likely to be subject to some latent processes (ie, 
unrecognized or unmeasurable: “gut-feeling”). It was sug-
gested that confounding by indication, therefore, cannot 
be measured directly and fully but only tangentially, if it is 
recognized at all.4
However, since then, 40 years have passed and four major 
developments have shifted this balance dramatically. First, 
two and a half decades after the introduction of evidence-
based medicine,5,6 physicians find themselves obligated 
to explore the rational arguments that must motivate each 
treatment decision. Therefore, the role of the immeasurable 
“gut-feeling” should be diminished completely. Second, 
increasing diagnostic testing and digitalization of test results 
has made the information physicians use for treatment deci-
sions more readily available to researchers. Third, increas-
ing regulation of randomized trials including monitoring, 
auditing, and traceability demands has greatly increased the 
logistical challenges of randomized trials. With these logis-
tical challenges, the cost also increases and consequently, 
the size of trials must be minimized to maintain economic 
viability. Fourth, it has been increasingly recognized that 
individualization of the evidence base for treatment deci-
sions is needed.7
The difficulties in applying results from randomized trials 
to individual patients have been described in some detail.8–10 
This problem is largely related to the limitations in size of tri-
als, as it could be solved by sufficiently subgrouping patients 
in the analyses. The potential impact of subgroup differences 
has been quantified by comparing the risk difference between 
high- and low-risk patients in 32 large randomized trials.11 
In these analyses, all but one showed a significant difference 
in treatment effectiveness between the highest and lowest 
risk quartiles.11
Here we present fictive numerical examples concerning 
blood transfusion in the ICU to illustrate conceptual consid-
erations instrumental to understanding both the power and the 
limitations of randomized trials. We argue that, in the current 
setting, randomization often comes at the price of a loss of 
personalization of medicine. In other words, randomization 
can be a powerful tool to help prove that a treatment can 
provide benefit to some, but it may also be what’s keeping 
us from proving in whom it will do so.
Why we randomize: confounding by 
indication
Every field of clinical medicine has some well-known 
examples of published observational research showing 
associations between treatment and outcome, which can be 
blamed on baseline incomparability between the treated and 
untreated groups.12 It is the problem of comparing apples 
and oranges. Patients with worse prognosis are either more 
or less likely to be treated and the observed outcome is in 
spite of treatment, rather than due to treatment. This is the 
problem of confounding by indication.12,13 Confounding by 
indication is the reason we randomize.1,14–16
Figure 1 illustrates the assumed true causal relation 
between blood transfusion and mortality in a fictive ICU 
 population. In Figure 1, the entire population is depicted in 
two mutually exclusive situations, both nontransfused (left 
panel) and transfused (right panel). This is called a coun-
terfactual representation of causality, because it is always 
“counter to the facts” (ie, it is impossible to observe in real 
life).17–19 Counterfactual comparisons are considered theoreti-
cally ideal for establishing causality, because they compare 
every individual in the treated situation to himself or herself 
in the untreated situation.17–19 Although even counterfactual 
theory has its limitations,20 it roughly corresponds to our 
intuitive understanding of causality (ie, would the same out-
come have occurred with treatment as without or vice versa).
For the simplified example in Figure 1, the population is 
divided into three different, equal-sized groups. The risk of 
death differs between these groups. If each group contains 
200 patients and the entire population was left nontransfused, 
we assume the following risks of death for the three groups 
considered: 20% for patients with cardiovascular disease, 
40% for patients with active bleeding, and 80% for patients 
with both cardiovascular disease and active bleeding. The true 
causal effect of blood transfusion is set at an absolute risk 
reduction of 10% for all patients for each of the three groups. 
This also corresponds to an average risk reduction of 10% 
for the entire population, in spite of a difference in baseline 
risk of death between the groups. This baseline difference 
in itself is insufficient to cause confounding by indication.
Confounding by indication arises from the combination of 
this difference in prognosis and a different treatment preva-
lence. Figure 2 illustrates both how confounding by indication 
can distort the true causal relation and how a randomized trial 
can estimate this relation correctly.
In panel A of Figure 2, the choice to treat or not to treat is 
left to the physician and the physician is more likely to trans-
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fuse patients with worse prognosis: 50 of 200 patients (25%) 
with cardiovascular disease, 100 of 200 (50%) with active 
bleeding, and 180 of 200 (90%) with both are transfused. 
These groups still also experience the previously assumed 
death risks of 20%, 40%, and 80% in the nontransfused 
patients. Although the absolute risk reduction for mortality 
is still assumed to be 10% for any of the three groups, the 
crude average risk difference for the total population is now 
an increase of 17%. This reversal of the true beneficial effect 
of blood transfusions into an increased risk of death occurs 
because the deaths from the higher risk groups (ie, active 
bleeding or both cardiovascular disease and active bleeding) 
weigh more heavily among the transfused patients, since 
the prevalence of transfusions is higher in these groups. In 
other words, the transfused group contains more seriously ill 
patients and is therefore not exchangeable with the nontrans-
fused group.17–19 The table under the graph also shows how 
the true effect can be correctly estimated through statistical 
correction, which takes a weighted average of the stratum-
specific risk reductions (ie, each stratum-specific absolute 
risk reduction is 10%, making the average also the true causal 
risk reduction of 10%, irrespective of the relative weights 
of the different strata). This approach creates what in coun-
terfactual theory is called conditional exchangeability.17–19 
Conditional on having a certain disease, the transfused and 
nontransfused patients are considered exchangeable, in terms 
of prognosis. Put differently, there is no confounding within 
strata of the three measured confounders.
In this simplified example, correction for the prognosis 
of the patient is straightforward. Conversely, in real life, con-
founding by indication is notoriously difficult to adequately 
correct for.13 Many different factors determine a patient’s 
prognosis and if any of these also influence a physician’s 
decision to prescribe a certain treatment, these will cause 
confounding by indication. If we do not know exactly which 
factors a physician weighted in his or her decision to treat 
a patient, we cannot measure these factors. If we have not 
measured these factors, it will be impossible to apply a sta-
tistical correction.
Panel B of Figure 2 shows how randomization can fix 
the problem of confounding by indication, without the need 
for statistical correction. As mentioned above, confounding 
by indication only occurs if the prevalence of treatment dif-
fers between groups of patients with different prognosis. By 
randomly assigning patients to be either treated or nontreated, 
the probability of being treated is made independent of prog-
nosis. Therefore, the prevalence of treatment is made equal 
between the groups of different prognosis. In the example 
Figure 1 True causal relation between blood transfusion and mortality in a fictive ICU population, which is either completely nontransfused or completely transfused.
Notes: Schematic representation of the hypothetical effects of blood transfusion in patients with different risk factor profiles. Three different profiles are considered: 
the presence of cardiovascular disease, active bleeding, or both. Solid gray bubbles represent nontransfused patients and patterned bubbles represent transfused patients. 
height of the position of the bubbles indicates the risk of death (%) and the size of the bubble represents the actual number of deaths. the table under each graph shows 
the represented numbers. the average risk of death (ie, the risk for the total population) can be calculated by dividing the total number of deaths (ie, added from all three 
subgroups) by the total population size. the risk of death differs between the groups. the effect of blood transfusion is a risk reduction of 10% for each of the three groups. 
As can be seen from the table under the graphs, this also corresponds to an average risk reduction of 10% (ie, from 47% to 37%). this average risk difference is not affected 
by the difference in baseline risk of death between the groups.
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Figure 2 Causal relationship distorted by confounding by indication and correctly estimated in a randomized trial.
Notes: Schematic representation of the hypothetical effects of blood transfusion in patients with different risk factor profiles. Three different profiles are considered: the 
presence of cardiovascular disease, active bleeding, or both. Solid gray bubbles represent nontransfused patients and patterned bubbles represent transfused patients. height 
of the position of the bubbles indicates the risk of death (%) and size of the bubble represents the actual number of deaths. the table under each graph shows the represented 
numbers. In panel A, in an observational study, there is confounding by indication. the true effect of transfusion (ie, a risk reduction of 10%) can still be estimated by statistical 
correction, but the crude analysis shows a risk increase of 17%. In real life, full statistical correction for confounding by indication is often impossible. In panel B, confounding 
is removed by randomization. therefore, the crude analysis correctly estimates the true effect of blood transfusion.
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they each contain 100 transfused and 100 nontransfused 
patients. This corresponds almost perfectly to the two situa-
tions depicted in Figure 1, except that all groups are half the 
size. We had to divide our population into two and transfuse 
only one half, because in real life, we cannot study the entire 
population in two mutually exclusive situations (ie, both 
nontransfused and transfused, such as depicted in Figure 1). 
Randomization is the closest we can possibly get to a real 
counterfactual situation.
The above example illustrates the reason we randomize. 
We do so to avoid confounding in situations where we cannot 
correct for it.1,14,15 Often, we attempt to correct for confound-
ing by indication but are unsure if we fully succeeded in doing 
so. In these situations, randomization will, on average, over 
many studies, provide valid evidence of the effectiveness of 
a treatment without the danger of incompletely corrected 
confounding by indication.
A problem randomization just can’t fix: 
effect modification
In spite of the tremendous power of randomized trials to pro-
vide us with highly reliable evidence of treatment effective-
ness, there remains a problem that randomization just cannot 
fix. In all of the previous discussions, we have assumed the 
effect of blood transfusions to be the same for all three patient 
groups considered. This is of course highly improbable.21 In 
fact, an expected difference in effectiveness is precisely what 
causes confounding by indication. A physician is more likely 
to transfuse a patient whom he or she thinks is more likely 
to benefit from that transfusion. In other words, if 90% of 
patients with both cardiovascular disease and active bleeding 
are transfused and only 25% of patients with cardiovascular 
disease alone, the physician apparently expects that patients 
with both cardiovascular disease and active bleeding are 
much more likely to benefit from receiving a transfusion. 
This expectation is based on something—if not on an actual 
well-documented, systematically gathered and identifiable, 
and objectively verifiable evidence base, then at least on 
extensive clinical experience.22
Whatever the exact basis for the clinical decision to 
transfuse one patient and not the other is, it is likely that 
the effect of transfusion will really be different between two 
patients. The effect will then be modified by the patient’s risk 
profile.21 Although the presence of effect modification does 
not necessarily detract from the validity of the conclusion of 
a randomized trial, it is important to be aware of how it can 
influence the results.23 To appreciate how effect modification 
influences the results of a randomized trial, we continue our 
simplified example with the three patient groups in Figure 3.
Panel A of Figure 3 shows a more realistic outcome of 
the randomized trial also depicted in panel B of Figure 2 (ie, 
an outcome showing effect modification across subgroups of 
patients). In this example transfusion has no effect on mortal-
ity in patients with cardiovascular disease alone. In patients 
with active bleeding, transfusion reduces the absolute risk 
of death by 10% and in patients with both cardiovascular 
disease and active bleeding, the absolute risk of death is 
reduced by 30%. Since this is a randomized trial, we assume 
no confounding. Therefore, both the crude and corrected 
effects give valid estimates of the true effect in this popula-
tion. This true effect is a population average reduction in 
risk of death of 13%.
Panel B of Figure 3 shows the target population to which 
the results of the randomized trial in panel A are going to 
be applied. As can be seen from the table under the graph, 
the absolute risk differences for each of the three groups are 
the same as observed in the randomized trial, reaffirming 
the validity of our estimates from that trial. For clarity we 
have assumed no confounding by indication in this target 
population. This can also be checked in the table under the 
graph where it is shown that all the three groups have 50% 
of their patients transfused. Therefore, prognosis and treat-
ment prevalence are again independent, and there can be no 
confounding by indication.
There is only one difference between the target population 
and the randomized trial in Figure 3. The risk factor distribu-
tion is different. There are more patients with cardiovascular 
disease alone and fewer with both cardiovascular disease and 
active bleeding in the target population. Therefore, there are 
more patients experiencing no effect at all and fewer patients 
experiencing the maximum effect of 30% reduction in the risk 
of death. As a consequence, the population average effect is 
much smaller. This effect is a 5% instead of a 13% reduction 
in the absolute risk of death. This is probably one of the most 
important reasons why treatments applied in daily clinical 
practice can have disappointingly little effect compared to 
expectations raised in randomized trials.
It also illustrates what important information is typically 
missing from the interpretation of results from randomized 
trials. Subgroup analyses would have told us to transfuse only 
patients with active bleeding, whether alone or in combina-
tion with cardiovascular disease. However, subgroup analyses 
are generally discouraged on the basis of a lack of power and 
the presumed danger of post hoc analyses. To allow subgroup 
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Figure 3 In the presence of effect modification, a randomized trial provides a completely valid effect estimate, which is, nonetheless, irrelevant for a target population with 
different risk factor distribution.
Notes: Schematic representation of the hypothetical effects of blood transfusion in patients with different risk factor profiles. Three different profiles are considered: the 
presence of cardiovascular disease, active bleeding, or both. Solid gray bubbles represent nontransfused patients and patterned bubbles represent transfused patients. height 
of the position of the bubbles indicates the risk of death (%) and size of the bubble represents the actual number of deaths. the table under each graph shows the represented 
numbers. There is effect modification by subgroup. There is no confounding by indication (ie, the crude and corrected risk differences are the same). Still it is clear that the 
distribution of patients over the subgroups is crucial. In panel A, a randomized trial was performed and the estimated risk difference was –13%. Panel B shows the target 
population (still without confounding by indication), the real risk difference in that population would be –5%. however, these are both estimates of the average risk difference. 
What we really want to know is that transfusing patients with cardiovascular disease alone would be useless, while transfusing patients with both cardiovascular disease and 
active bleeding would result in a risk difference of –30%. the only way to know this is to perform subgroup analyses.
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analyses, they have to be prespecified, which in turn means 
that a trial has to be sufficiently powered. This power should 
allow for three considerations. First, each subgroup should 
be of sufficient size, meaning the required trial size is inflated 
by a factor roughly equal, but usually bigger than the number 
of intended subgroup categories. Second, the power to show 
a difference in effect size between groups is usually smaller 
than the power to show the presence of an effect within a 
group. This even holds true if no effect is expected in one 
of the groups, because this lack of effect is estimated with 
a margin of uncertainty, while normal hypothesis testing 
takes the null hypothesis as a fact without uncertainty. This 
means a further inflation of trial size. Third, some kind of 
allowance will have to be made for multiple testing. All in 
all, the correct implementation of subgroup analyses in a 
randomized trial will cause the trial to be at least several 
times and often orders of magnitude larger than a similar 
trial without subgroup analyses. The way randomized trials 
are currently performed, including all regulations that have 
to be complied with, usually makes a trial that is sufficiently 
powered for extensive subgroup analyses financially impos-
sible. Subgroups, in conclusion, are things better not meddled 
with in randomized trials. Subgroups, unfortunately, are also 
exactly what we need to allow clinically meaningful inter-
pretation of trial results.
If randomized trials are poorly suited for addressing 
effect modification and clinical decision-making needs reli-
able information on effect modification, can observational 
studies provide the necessary evidence? This question brings 
us back to our initial problem: confounding by indication.
Real-life situation: confounding by 
indication and effect modification
In real life, we are stuck with a seemingly intractable com-
bination of two problems. First, we need an estimate free of 
the distortive effect of confounding by indication. This is the 
reason we do randomized trials. Second, we need to estimate 
subgroup-specific effects. For reasons of practicality, this is 
effectively impossible in randomized trials. We therefore 
seem to have arrived at an impasse.
However, the fact that the only reason to randomize is 
to avoid confounding in no way implies confounding by 
indication to be solvable only by randomization. As can be 
seen from Figure 4, there is no confounding by indication 
Figure 4 The most likely real-life situation: both confounding by indication and effect modification influence the results.
Notes: Schematic representation of the hypothetical effects of blood transfusion in patients with different risk factor profiles. Three different profiles are considered: the 
presence of cardiovascular disease, active bleeding, or both. Solid gray bubbles represent nontransfused patients and patterned bubbles represent transfused patients. height 
of the position of the bubbles indicates the risk of death (%) and size of the bubble represents the actual number of deaths. the table under each graph shows the represented 
numbers. There are both confounding by indication and effect modification. This is the most likely scenario for most clinical situations. It is clear (from the relative positions 
of the bubbles and the risk differences in the table) that within strata of subgroup, this situation is comparable to the situation in Figure 3. To estimate the influence of effect 
modification, we need to perform subgroup analyses. If we perform subgroup analyses, confounding by indication becomes irrelevant, because within subgroup analyses risk 
difference is unaffected by this confounding (see also panel A of Figure 2).
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within subgroups. Obviously, in this dramatically simplified 
example, it is easy to identify all three relevant subgroups, 
while in real life, there may be dozens of unknown confound-
ers. However, as argued before, all these confounders are 
confounders because, and only because, the physician expects 
them to be effect modifiers. The physician is more likely to 
treat a patient in which he or she expects the biggest treatment 
benefit. In this way she turns prognostic indicators, which 
are associated with expected benefit (ie, expected effect 
modifiers) into real confounders. A critical physician should 
then demand evidence of this effect modification, since this 
is instrumental to informed clinical decision-making. It 
would be impossible to practice any form of evidence-based 
medicine without asking oneself “why should I treat this 
particular patient while I do not treat that other one?” This 
means effect modification has to be quantified and to do so, 
these confounders have to be identified, because we need 
subgroup analyses for each and every one of them. Once these 
confounders have been identified, such subgroup analyses 
are much more efficiently carried out in observational than 
in randomized trials. Simply because observational research 
can be carried out at much lower financial and ethical costs. 
Further, since these subgroup analyses will also solve the 
problem of confounding by indication, randomization is no 
longer needed anyway. Finally, identification of confounders 
relies entirely on physicians making explicit why they chose 
to treat one patient and not the other.
It may seem like a daunting task to identify all patient 
characteristics weighted in a treatment decision, but in this 
age of evidence-based medicine it is the only way to per-
sonalize our treatments. Without personalization, almost all 
patients will be overtreated or undertreated.22 It may therefore 
well be time to finally start seriously working at this daunting 
task, as it is the only way to truly personalize medicine in an 
evidence-based way.
Discussion
In the above, we have argued that, although randomization is 
an immensely powerful tool against confounding by indica-
tion, personalization of medicine requires the quantification 
of effect modification by different risk groups, rather than 
effects averaged over multiple risk groups. Further, the 
required subgroup analyses necessitate a sample size that 
would make most randomized trials prohibitively expensive. 
Therefore, we should seriously consider making a start at 
identifying and measuring all possible effect modifiers in 
observational research, or risk never making any meaning-
ful progress in the personalization of medicine. The obvious 
limitation in our “call to observational clinical research” lies 
in the effectiveness of the proposed approach to really deal 
with all relevant confounding by indication and provide us 
with valid estimates of the effects of treatments.
To validly estimate the effects of treatment, we need to 
establish conditional exchangeability.17–19 We will arguably 
never be entirely sure whether we achieved this goal or 
not.17–19 However, this is in its essence not different from a 
randomized trial, in which we assume all prognostic factors to 
be equally distributed by chance, but get no guarantee.24 This 
is the reason we always include a “Table 1” with all important 
prognostic indicators. We know that, by chance alone, the 
prognosis can be different between the treated and untreated, 
and there will not be exchangeability. We can only be sure of 
the absence of confounding by coincidence over an infinite 
number of trials, which again is a theoretical impossibility.24 
There are two main considerations in achieving conditional 
exchangeability in observational research. First, have we 
identified and accurately measured all relevant confounders? 
Second, have we modeled them correctly?
The first consideration we have briefly hinted at already. 
In many fields of epidemiology, confounding can never be 
expected to be solved completely, due to the presence of 
unmeasured or unmeasurable confounders.25,26 However, in 
clinical epidemiology, confounding is caused by a physician’s 
decision to treat a patient. Therefore, it is theoretically impos-
sible to have truly unknown and unknowable  confounders. 
The physician has to know; otherwise the variable can never 
influence the decision. Unmeasured genetic variants, for 
example, could be effect modifiers and interesting targets for 
further research, but are not a concern as possible confound-
ers, because they cannot influence the physician’s decision. By 
the same token, measurement error cannot result in residual 
confounding. As long as we assure that we correct with the 
same measurement error that the physician used in his or her 
decision, we are still correcting completely for the confounding 
that the physician introduced. If the physician knows, it should 
be possible, with the help of that physician, to record the con-
founding variable with the same accuracy the physician used.
The second consideration has to do with the modeled form 
of the relation among the confounder, the treatment, and the 
outcome.27,28 We have not discussed this issue yet and have 
assumed statistical correction to be perfect throughout. This 
is a simplification of reality, but not one that could invalidate 
our conclusion that more observational research is needed. 
To be able to more accurately correct for a confounder, more 
data are needed. This is actually the main reason we consider 
observational research preferable for the quantification of 
effect modification: in observational research, it is easier (ie, 
cheaper) to gather more data.
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Personalization of medicine
In conclusion, the personalization of medical decision-
making could greatly be enhanced by using more observa-
tional clinical research. However, great care should always be 
taken with respect to confounding by indication, and conclu-
sions from observational research should never be accepted 
lightly. Appropriate appreciation of the evidence provided 
by different observational studies might require much more 
active discussion in the medical literature, instead of the cur-
rent, often limited interaction between authors and readers.
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